Milberg Weiss Announces Investigation Relating to Class Action Lawsuits Filed on Behalf of Certain Investors of Warner Chilcott Limited -- WCRX

19 November 2006

The law firm of Milberg Weiss Bershad & Schulman LLP announces that it is investigating possible illegal conduct as alleged in class action lawsuits filed by certain law firms on behalf of investors in Warner Chilcott Limited ("Warner Chilcott" or the "Company") (NASDAQ: WCRX) who purchased the common stock of Warner Chilcott pursuant and/or traceable to the Company's Registration Statement and Prospectus for its initial public offering on or about September 20, 2006 (the "IPO").

The class actions are pending in the United States District Court for the Southern District of New York against Warner Chilcott and certain of its officers and directors. The complaints in the above-referenced actions allege that Warner Chilcott and certain of its officers and directors violated the Securities Act of 1933 and/or the Securities Exchange Act of 1934. If you purchased the common stock of Warner Chilcott pursuant and/or traceable to the Company's Registration Statement and Prospectus for its IPO on or about September 20, 2006, you may, no later than January 2, 2007, request that the Court appoint you as lead plaintiff. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. To be appointed lead plaintiff, the Court must decide that your claim is typical of the claims of other class members, and that you will adequately represent the class. Your share in any recovery will not be enhanced or diminished by the decision whether or not to serve as a lead plaintiff. You may retain Milberg Weiss Bershad & Schulman LLP, or other attorneys, to serve as your counsel in this action.

The complaint in one of the above-referenced actions alleges that Warner Chilcott develops, manufactures, sells and markets branded prescription pharmaceutical products in women's healthcare and dermatology. Moreover, the complaint alleges that the Registration Statement and Prospectus issued in connection with the IPO was materially false and misleading because it failed to disclose, among other things, that at the time of the IPO, the Company had stopped shipping one of its best selling products, namely Ovcon 35, a birth control pill, and that, as a result, the Company had eliminated a key source of revenue.

According to the complaint, on September 26, 2006, Warner Chilcott issued a press release announcing that it had filed a supplement to the Registration Statement and Prospectus that disclosed that the Company had ceased shipments of Ovcon 35 in September 2006 and that it had launched a new product, Ovcon Chewable. In reaction to this news, the price of Warner Chilcott common shares fell $2.40 per share, or 16 percent, from its closing price of $15.00 on September 25, 2006, to close at $12.60 per share on September 26, 2006, on unusually heavy trading volume.

Milberg Weiss Bershad & Schulman LLP is one of the nation's most experienced law firms representing individual and institutional investors and is active in major litigations pending in federal and state courts throughout the United States. Milberg Weiss has taken a leading role in many important actions on behalf of defrauded investors, consumers, and others for nearly 40 years. Please visit the Milberg Weiss website (http://www.milbergweiss.com) for more information about the firm. If you wish to discuss this action with us, or have any questions concerning your rights and interests with regard to this case, please contact the following attorneys:

Lori G. Feldman Anita B. Kartalopoulos One Pennsylvania Plaza, 49th Fl. New York, NY, 10119-0165 Phone number: (800) 320-5081 Email: contactus@milbergweiss.com Website: http://www.milbergweiss.com

SOURCE: Milberg Weiss Bershad & Schulman LLP

Source: marketwire

All trademarks and copyrighted information contained herein are the property of their respective owners.